All News

bone.infection.gram_.rod_.jpg

Wiki Guidelines Approach to Pyogenic Osteomyelitis

d Jack Cush, MD

A crowd sourced, WikiGuidelines approach to clinical treatment guideline development for pyogenic osteomyelitis yielded 7 important clinical questions, 2 clear treatment recommendations and 5 topic reviews to inform future treatment or investigations.

Read Article
psoriasis,arm,hand,rash,elbow

Bimekizumab's Favorable Safety Profile in Psoriasis

d Jack Cush, MD

A 2-year safety study of bimekizumab, the dual IL-17A/F inhibitor, plaque psoriasis patients showed bimekizumab (BMK), to be effective, well tolerated, with no new safety concerns other than a modest risk of oral candidiasis.

Read Article
PsA,Pod,RNL

RNL 2022: Psoriatic Arthritis Advances

d Jack Cush, MD

Tuesday Nite Rheumatology on 10 May 2022 featured session highlights from RheumNow Live 2022.



This webinar presented exerpts from these lectures along with audience Q & A

Read Article
RA.Ow02.jpg

ASCORE: Seropositivity Favors Abatacept Drug Survival

d Jack Cush, MD

The ASCORE (Abatacept SubCutaneOus in Routine clinical practicE) study evaluated efficacy, safety, and drug retention (durability) of abatacept (ABA) moderate-to-severe rheumatoid arthritis (RA) and found consistently better ABA durability in those who were seropositive. 

Read Article
We had a great TNR this week. Playback now available in case you missed it. This webinar presented excerpts from these lectures along with Q & A Psoriatic Arthritis Guidelines Drug Targeting in PsA PsA Registries and Real World Data https://t.co/al17KLQm0j https://t.co/O4SvMU37Lg

Links:

Dr. John Cush RheumNow ( View Tweet)
Early inflammatory arthritis pts (n=35,807; 86% White & 5,164 ethnic minority). Whites & minorities were equally seen by rheum <3 wks & started on Rx < 6wks, <inorities had less remission @3 mos (OR 0.79) or recv MTX 1st or steroids(0.68-0.63) https://t.co/rK7GLt5n1X https://t.co/uUwBBCnyGL

Links:

Dr. John Cush RheumNow ( View Tweet)
Doctor Survey: how many Rheumatic/Autoimmune pts do you have on Evusheld (PrEP)?

Dr. John Cush RheumNow ( View Tweet)

ASCORE: Seropositivity Favors Abatacept Drug Survival The ASCORE study evaluated efficacy, safety, and drug retention (durability) of ABA in moderate-to-severe RA and found consistently better ABA durability in those who were seropositive. https://t.co/n855mvkaoT https://t.co/1nCjL89Bfw

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 218 primary APS w/ Thrombocytopenia in 74 (34%) - such pts had signif. more visceral venous thromboses (13.5% vs. 3.5%), hemolytic anemia (27% vs. 12%), low C3/C4 (26% vs 11%), & higher pregnancy morbidity (HR 8.0, p = 0.0006) https://t.co/U9drB3gWq2 https://t.co/0EwItMO9N1

Links:

Dr. John Cush RheumNow ( View Tweet)
Making You the Expert of You! (Smart Rules for Patients) You’ve scheduled an appointment with your medical provider - how do you make the most of it? https://t.co/62mTqk4ksL https://t.co/gr7Hvt7EI3

Links:

Dr. John Cush RheumNow ( View Tweet)
Polygenic Risk Scores to Identfy Severe Knee and Hip Osteoarthritis This study identified genetic risk variants from genome-wide association analysis of OA patients to calculate PRSs associated with subsequent need for joint replacement surgery. https://t.co/65llG1nULF https://t.co/YQAJ9tIluF

Links:

Dr. John Cush RheumNow ( View Tweet)
New download available! Smart rules for patients—a patient handout. https://t.co/8yjCwb95c5 https://t.co/baFOavYO99

Links:

Dr. John Cush RheumNow ( View Tweet)
Diagnostic Delays in Spondyloarthritis Still Prolonged Previously quoted average delay in diagnosing axSpA may be improving as a recent UK study shows the mean average time to diagnosis in two different NHS trusts was between 5 and 6 years. https://t.co/6T9pck7nLa https://t.co/nwGBef2Gja

Links:

Dr. John Cush RheumNow ( View Tweet)
Our response to statins is influenced by our gut microbiome https://t.co/xKZdxO13va New @MedCellPress https://t.co/BxwhRhMAX9

Links:

Eric Topol EricTopol ( View Tweet)
Lumbar spinal stenosis affects 103 million worldwide (11% of older adults in US). 1st line Rx is activity modification, analgesia, PT. Benefits of epidural steroids havent been established. Decompressive surgery only for selected pts w/ pain & limitation https://t.co/VvKZaeVumy https://t.co/1shpS0Ajn4

Links:

Dr. John Cush RheumNow ( View Tweet)
Interested in what we covered in the month of April? You can find all our PsA content at the link below. What was your biggest takeaway from our PsA All the Way campaign? https://t.co/hl0HKggULj https://t.co/O1QMibJ4qA

Links:

Dr. John Cush RheumNow ( View Tweet)
NEJM has published results of 2 phase 3 trials (BRAVE-AA1, BRAVE-AA2) demonstrating the efficacy of Baricitinib in aduls with severe alopecia areata - BARI was superior to placebo in hair regrowth by week 36 https://t.co/W6kjahdLEu https://t.co/QyTmlhb235

Links:

Dr. John Cush RheumNow ( View Tweet)
Lack of Research Stymies Uptake of Medical Marijuana for Rheumatic Pain An interesting read from @CreakyJoints. Check it out our synopsis. https://t.co/dHlUrWcyjB https://t.co/pL5Sn5eD7h

Links:

Dr. John Cush RheumNow ( View Tweet)
Comparison of NHANES survey data from 2 eras (2007–2008 and 2017–2018) shows that prevalence blood pressure control decreased from 65% to 55% over 10 yrs(P=0.03); while lipid control remained stable; and diabetes med use rose 71% to 95% https://t.co/WIWBCYo2Yi https://t.co/mS7uVIiyUq

Links:

Dr. John Cush RheumNow ( View Tweet)
Prophylaxis against pneumocystis pneumonia in RA patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry https://t.co/zeDQpP1NEH proph reduced PCP by 3/1000 per yr, 5 pts PCP despite proph, 80% on MTX & 11% cease proph due to AEs!

Links:

Peter Nash drpnash ( View Tweet)

×